Axim Biotechnologies annual operating margin
2015
2016
2017
2018
2019
2021
2022
2023
Axim Biotechnologies's operating margin was −6,960.98% for fiscal 2023.
View full Axim Biotechnologies company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −6,960.98% | +45464.62 pp |
| 2022 | 2022-12-31 | −52,425.60% | −29311.15 pp |
| 2021 | 2021-12-31 | −23,114.45% | −22725.60 pp |
| 2019 | 2019-12-31 | −388.86% | +2185.67 pp |
| 2018 | 2018-12-31 | −2,574.53% | +4044.95 pp |
| 2017 | 2017-12-31 | −6,619.48% | +1369.34 pp |
| 2016 | 2016-12-31 | −7,988.83% | +12462.44 pp |
| 2015 | 2015-12-31 | −20,451.26% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2024 | 2024-06-30 | −3,257.86% | +3769.32 pp |
| Q1 2024 | 2024-03-31 | −757.97% | +8849.09 pp |
| Q4 2023 | 2023-12-31 | −5,978.44% | +9125.44 pp |
| Q3 2023 | 2023-09-30 | −6,142.73% | +94155.60 pp |
| Q2 2023 | 2023-06-30 | −7,027.18% | +151997.65 pp |
| Q1 2023 | 2023-03-31 | −9,607.06% | +30733.24 pp |
| Q4 2022 | 2022-12-31 | −15,103.88% | −441.43 pp |
| Q3 2022 | 2022-09-30 | −100,298.33% | −97639.75 pp |
| Q4 2021 | 2021-12-31 | −159,024.83% | −159057.03 pp |
| Q3 2021 | 2021-09-30 | −40,340.30% | −26896.37 pp |
| Q2 2021 | 2021-06-30 | −14,662.44% | −14229.35 pp |
| Q1 2021 | 2021-03-31 | −2,658.58% | +12377.18 pp |
| Q4 2019 | 2019-12-31 | 32.20% | +16437.90 pp |
| Q1 2019 | 2019-03-31 | −13,443.93% | +847.18 pp |
| Q4 2018 | 2018-12-31 | −433.09% | +6362.96 pp |
| Q3 2018 | 2018-09-30 | −15,035.76% | −2891.40 pp |
| Q2 2018 | 2018-06-30 | −16,405.70% | −4708.30 pp |
| Q1 2018 | 2018-03-31 | −14,291.11% | −11732.97 pp |
| Q4 2017 | 2017-12-31 | −6,796.05% | −489.45 pp |
| Q3 2017 | 2017-09-30 | −12,144.36% | +4059.51 pp |
| Q2 2017 | 2017-06-30 | −11,697.41% | −7325.15 pp |
| Q1 2017 | 2017-03-31 | −2,558.14% | +4169.31 pp |
| Q4 2016 | 2016-12-31 | −6,306.60% | +34615.41 pp |
| Q3 2016 | 2016-09-30 | −16,203.88% | −8377.48 pp |
| Q2 2016 | 2016-06-30 | −4,372.25% | +8511.66 pp |
| Q1 2016 | 2016-03-31 | −6,727.45% | — |
| Q4 2015 | 2015-12-31 | −40,922.01% | — |
| Q3 2015 | 2015-09-30 | −7,826.39% | — |
| Q2 2015 | 2015-06-30 | −12,883.91% | — |
Over the last five reported fiscal years, Axim Biotechnologies's operating margin decreased from −6,619.48% to −6,960.98%, a change of −341.49 percentage points. The latest reported quarter, Q2 2024, shows −3,257.86%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Axim Biotechnologies filings at SEC.gov ↗